T. Rowe Price Associates
CADL icon

T. Rowe Price Associates’s Candel Therapeutics CADL Stock Holding History

T. Rowe Price Associates’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Buy
52,732
+22,622
+75% +$171K ﹤0.01% 2592
2026
Q1 		$148K Buy
30,110
+4,296
+17% +$23.4K ﹤0.01% 2916
2025
Q4 		$146K Buy
25,814
+6,176
+31% +$33.2K ﹤0.01% 2887
2025
Q3 		$101K Hold
19,638
– – ﹤0.01% 2922
2025
Q2 		$100K Buy
19,638
+7,363
+60% +$37.9K ﹤0.01% 2891
2025
Q1 		$70K Buy
+12,275
New +$100K ﹤0.01% 2885

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates's CADL Position: Q2 2026 in Review

T. Rowe Price Associates increased its Candel Therapeutics (CADL) stake by 75% in Q2 2026, buying an estimated $171K and bringing the position to 52,732 shares worth $544K. The position accounts for ﹤0.01% of the portfolio, ranked #2592.

T. Rowe Price Associates first reported a position in CADL in Q1 2025 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • T. Rowe Price Associates held 52,732 shares of Candel Therapeutics worth $544K as of Q2 2026.
  • T. Rowe Price Associates bought 22,622 Candel Therapeutics shares in Q2 2026, an estimated $171K.
  • Candel Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2592 holding.
  • T. Rowe Price Associates first reported a position in Candel Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.